DOV-216,303
id:
dov-216-303-196-6133297
title:
DOV-216,303
text:
DOV 216,303 is an experimental antidepressant drug originally developed by DOV Pharmaceutical and was licensed to Merck & Co. in 2004; Merck and DOV terminated their relationship in December 2006. It is a triple reuptake inhibitor (TRI), or serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI). It is the racemic mixture of amitifadine (DOV-21,947) and its (–)-enantiomer, DOV-102,677. Its IC50 values for SERT, NET, and DAT are Ki 14 nM, 20 nM, and 78 nM, respectively. As of March 2008, DOV
brand slug:
wiki
category slug:
encyclopedia
description:
Chemical compound
original url:
https://en.wikipedia.org/wiki/DOV-216,303
date created:
date modified:
2022-11-21T18:19:03Z
main entity:
{"identifier":"Q5205904","url":"https://www.wikidata.org/entity/Q5205904"}
image:
{"content_url":"https://upload.wikimedia.org/wikipedia/commons/b/b7/DOV-216%2C303.svg","width":512,"height":469}
fields total:
13
integrity:
15